Stratipath is an AI company dedicated to revolutionising cancer treatment decisions by assisting physicians in decision support. Our first solution, Stratipath Breast, is the first AI-based prognostic risk profiling tool, regulatory aligned for clinical use in the EU and the UK. The solution analyses cancer tissue, enabling the identification of patients with high, or low, risk of disease progression. It is already in clinical use and validated in large-scale studies.
